Questionnaire

1. In light of the advent of biologic therapies, proposed new criteria for clinical definitions of asthma remission include:

2. Airways inflammation can be controlled with ICS in patients with asthma that is:

3. In asthma, elevated BEC is a powerful biomarker for:

4. An example of an anti-IL-5R monoclonal antibody that targets eosinophilic inflammation in severe asthma is:

5. Real-world data demonstrate that 75% of biologic-naïve and 65% of biologic-switch patients with severe asthma become exacerbation-free within one year of benralizumab therapy, and that most patients could stop regular ICS/LABA without a loss of asthma control or increase in asthma exacerbations.

6. The biologic that seemingly is most efficacious for the treatment of severe child-onset asthma is:

7. In terms of T2 eosinophilic inflammation, FeNO is the best biomarker of:

8. Strong associations indicate that worsening of COPD symptoms and exacerbations can lead to cardiovascular events and premature death.

9. The risk of a severe cardiovascular event in the first seven days after a COPD exacerbation of ANY severity is increased:

10. Among pharmacological interventions to reduce mortality risk in patients with COPD, clinical and real-world data indicate the most efficacious to be: